Dosage and Administration
Simparica Trio is given orally once a month, at the recommended minimum dose of 0.54 mg/lb (1.2 mg/kg) sarolaner, 0.011 mg/lb (24 µg/kg) moxidectin, and 2.27 mg/lb (5 mg/kg) pyrantel (as pamoate salt).
View Simparica Trio Drug Facts Sheet.
|Body Weight||Sarolaner per Tablet (mg)||Moxidectin per Tablet (mg)||Pyrantel per Tablet (mg)||Number of Tablets Administered|
|2.8 to 5.5 lbs.||3||0.06||12.5||One (Yellow)|
|5.6 to 11.0 lbs.||6||0.12||25||One (Purple)|
|11.1 to 22.0 lbs.||12||0.24||50||One (Blue)|
|22.1 to 44.0 lbs.||24||0.100||50||One (Blue)|
|44.1 to 88.0 lbs.||48||0.96||200||One (Green)|
|88.1 to 132.0 lbs.||72||1.44||300||One (Brown)|
|>132.1 lbs.||Administer the appropriate combination of tablets|
Simparica Trio can be offered by hand, in the food, or administered like other tablet medications. Care should be taken that the dog consumes the complete dose, and treated animals should be observed for a few minutes to ensure that part of the dose is not lost or refused. If a dose is missed, administer Simparica Trio and resume a monthly dosing schedule.
Simparica Trio should be administered at monthly intervals.See the Simparica Trio difference
Compare the labels of other products with Simparica Trio
Simparica Trio should be administered at monthly intervals year‑round or at least within one month of the animal’s first seasonal exposure to mosquitoes and continuing until at least 1 month after the dog’s last seasonal exposure. If a dose is missed, give Simparica Trio immediately and resume monthly dosing. When replacing a monthly heartworm preventive product, Simparica Trio should be given within one month of the last dose of the former medication.
Flea Treatment and Prevention
Treatment with Simparica Trio may begin at any time of the year. In areas where fleas are common year-round, monthly treatment with Simparica Trio can continue the entire year without interruption.
To minimize the likelihood of flea re-infestation, it is important to treat all dogs and cats within a household with an approved flea control product.
Tick Treatment and Control
Treatment with Simparica Trio can begin at any time of the year (see Effectivenes).
Intestinal Nematode Treatment and Control
For the treatment of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina) and adult hookworm (Ancylostoma caninum and Uncinaria stenocephala) infections, Simparica Trio should be administered once as a single dose. Monthly use of Simparica Trio will control any subsequent infections.
How to Store Simparica Trio
Store at or below 30°C (86°F). Keep away from children and pets.
There are no known containdications for the use of Simparica Trio.
Sarolaner, one of the ingredients in Simparica Trio, is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders.
Prior to administration of Simparica Trio, dogs should be tested for existing heartworm infections. Infected dogs should be treated with an adulticide to remove adult heartworms. Simparica Trio is not effective against adult D. immitis.
The safe use of Simparica Trio has not been evaluated in breeding, pregnant, or lactating dogs.
Just one Simparica Trio chewable delivered fully effective heartworm disease protection
In two well-controlled laboratory studies, a single oral dose of Simparica Trio was 100% effective in preventing the development of heartworm disease in dogs inoculated with infective larvae 30 days before treatment.
Simparica Trio was designed for balancing optimal effectiveness with safety to prevent heartworm disease
Possible Side Effects
In a field safety and effectiveness study, Simparica Trio was administered to dogs for the prevention of heartworm disease. The study included a total of 410 dogs treated once monthly for 11 treatments (272 treated with Simparica Trio and 138 treated with an active control). Over the 330 day study period, all observations of potential adverse reactions were recorded. The most frequent reactions reported in the Simparica Trio group are presented in the following table.
|Dogs with Adverse Reactions|
|Clinical Sign||Simparica Trio n=272||Active Controln=138|
In a second field safety and effectiveness study, Simparica Trio was administered to 278 dogs with fleas. Adverse reactions in dogs treated with Simparica Trio included diarrhea.
In a third field safety and effectiveness study, Simparica Trio was administered to 120 dogs with roundworms. Adverse reactions in dogs treated with Simparica Trio included diarrhea and vomiting.
Simparica Trio Important Safety Information
Use with caution in dogs with a history of seizures. Simparica Trio contains sarolaner, a member of the isoxazoline class, which has been associated with neurologic adverse reactions including tremors, ataxia, and seizures in dogs with or without a history of neurologic disorders. The safe use of Simparica Trio has not been evaluated in breeding, pregnant, or lactating dogs. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea. See full Prescribing Information, attached.
In two well controlled laboratory studies, a single oral dose of Simparica Trio was 100% effective in preventing the development of adult D. immitis in dogs inoculated with infective larvae 30 days before treatment.
In a well controlled US field study consisting of 246 dogs administered Simparica Trio and 119 administered an active control, no dogs treated with Simparica Trio tested positive for heartworm disease. All dogs treated with Simparica Trio were negative for D. immitis antigen and blood microfilariae at study completion on day 330.
Flea Treatment and Prevention
In a well controlled laboratory study, Simparica Trio began to kill fleas at 4 hours and demonstrated 100% effectiveness at 8 hours after initial administration. After weekly re-infestations, Simparica Trio reduced the number of live fleas by 97.8% within 12 hours of infestation for 28 days.
In a separate well controlled laboratory study, Simparica Trio demonstrated 100% effectiveness against adult fleas within 24 hours following treatment and maintained ?99.7% effectiveness against weekly re-infestations for 35 days.
In a study to explore flea egg production and viability, Simparica Trio killed fleas before they could lay eggs for 35 days.
In a well-controlled 60-day US field study conducted in dogs with existing flea infestations of varying severity, the effectiveness of Simparica Trio against fleas on Day 30 and 60 visits was 99.0% and 99.7%, respectively, compared to baseline. Dogs with signs of flea allergy dermatitis showed improvement in erythema, papules, scaling, alopecia, dermatitis/pyodermatitis and pruritus as a direct result of eliminating fleas.
Tick Treatment and Control
In a well controlled laboratory study, Simparica Trio began to kill existing I. scapularis within 8 hours, Simparica Trio reduced the number of live ticks by ?94.2% within 24 hours of infestation for 28 days.
In well controlled laboratory studies, Simparica Trio demonstrated ?98.9% effectiveness against an existing infestation of Amblyomma maculatum, Ixodes scapularis, Rhipicephalus sanguineus, and Dermacentor variabilis 48 hours post?administration and maintained ?90.4% effectiveness 48 hours after re-infestation for at least 28 days. Against Amblyomma americanum, Simparica Trio demonstrated ?99.4% effectiveness 72 hours after treatment of existing infestations, and maintained ?98.4% effectiveness 72 hours after re-infestation for at least 28 days.
Intestinal Nematode Treatment and Control
Elimination of roundworms (immature adult and adult Toxocara canis and adult Toxascaris leonina) and adult hookworms (Ancylostoma caninum and Uncinaria stenocephala) was demonstrated in well controlled laboratory studies.
In a 10-day multi-center field study, Simparica Trio was effective against Toxocara canis and reduced fecal egg counts 99.2%.
Margin of Safety
Simparica Trio was administered orally to 8 week old Beagle puppies at doses of 1, 3, and 5X the maximum labeled dose (2.4 mg/kg sarolaner, 48 µg/kg moxidectin, and 10 mg/kg pyrantel) at 28 day intervals for 7 treatments. Dogs in the control group received placebo. There were no clinically relevant, treatment related effects on clinical observations, body weights, food consumption, clinical pathology (hematology, coagulation, serum chemistry, and urinalysis), gross pathology, histopathology, or organ weights. During the end of study ophthalmic examination, the following change was found: one 1X dog had retinal dysplasia (OS folds).
Ivermectin-sensitive Collie Safety
Simparica Trio was administered orally once at 1, 3 and 5X the maximum labeled dose to Collies that had been pre-screened for avermectin sensitivity. Dogs in the control group received placebo. Clinical signs (ataxia, muscle fasciculations, mydriasis) associated with avermectin sensitivity were observed in the 5X group. All dogs were completely recovered by the third day of the study.
Simparica Trio was administered orally at 1 and 3X the maximum labeled dose at 28 day intervals for 3 treatments to Beagle dogs with patent adult heartworm infections and circulating microfilariae. Dogs in the control group received placebo. Diarrhea occurred more commonly in the treated dogs and also more often in the 3X group compared with the 1X group. Two dogs (1 each in 1X and 3X) developed a fever less than 24 hours after the first dose. The fever may have been a transient reaction to a rapid microfilaria reduction. Both dogs recovered without treatment.
In three well-controlled field studies, Simparica Trio was used concurrently with other medications such as vaccines, antimicrobials, anthelmintics, antiprotozoals, steroidal and non-steroidal anti-inflammatory agents, anesthetic agents and analgesics. No adverse reactions were associated with the concurrent use of Simparica Trio and other medications.